Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

EC grants orphan drug status to Dicerna’s DCR-A1AT to treat congenital A1AT deficiency

pharmaceutical-business-reviewDecember 20, 2019

Tag: Dicerna , DCR-A1AT , A1AT , Orphan Drug , EC

PharmaSources Customer Service